San Diego, January 16, 2026
Robbins LLP has initiated a class action lawsuit against Vistagen Therapeutics, alleging that the company misled investors regarding its Phase 3 PALISADE-3 trial results for its drug, fasedienol. Investors who acquired common stock between April 2024 and December 2025 are eligible for participation. The lawsuit states that the trial did not achieve its primary endpoint, leading to a drastic drop in stock price following the announcement of the trial’s failure.
San Diego, CA
Robbins LLP Initiates Class Action Against Vistagen Therapeutics, Inc. Over Alleged Misleading Trial Results
San Diego, CA – Robbins LLP has filed a class action lawsuit on behalf of investors who purchased or acquired Vistagen Therapeutics, Inc. (NASDAQ: VTGN) common stock between April 1, 2024, and December 16, 2025. The lawsuit alleges that Vistagen misled investors regarding the viability of its Phase 3 PALISADE-3 trial of fasedienol for treating social anxiety disorder.
The complaint asserts that Vistagen made positive statements about the trial’s progress while concealing material adverse facts. Specifically, the company failed to disclose that the PALISADE-3 study did not achieve its primary endpoint, showing no significant improvement with fasedienol compared to a placebo. This omission led investors to purchase shares at artificially inflated prices.
On December 17, 2025, Vistagen announced the trial’s failure to meet its primary endpoint. In response, the company’s stock price plummeted from $4.36 per share on December 16, 2025, to $0.86 per share on December 17, 2025, marking a decline of over 80%.
Investors who wish to serve as lead plaintiffs in the class action are encouraged to contact Robbins LLP. Lead plaintiffs represent the class in directing the litigation. Participation in the case is not required to be eligible for a recovery. All representation is on a contingency fee basis, meaning shareholders pay no fees or expenses unless a recovery is obtained.
Robbins LLP is a law firm specializing in securities class actions, shareholder derivative actions, and other complex commercial litigation. The firm has a history of securing significant recoveries for investors and has been involved in numerous high-profile cases.
Vistagen Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for neuropsychiatric and neurological disorders. The company’s lead product candidate, fasedienol, is an intranasal neuroactive steroid being evaluated for the acute treatment of social anxiety disorder.
As of January 16, 2026, Vistagen’s stock (NASDAQ: VTGN) is trading at $0.671 per share, reflecting a decrease of 4.02% from the previous close. The day’s trading range has seen a high of $0.722 and a low of $0.6656, with an opening price of $0.71 and a volume of 936,291 shares.
Investors seeking more information or wishing to discuss their potential involvement in the class action can contact Robbins LLP at 1-800-350-6003 or visit their website. The firm offers free investment monitoring and notifications to keep investors informed about developments in securities class actions.
This article is for informational purposes only and does not constitute legal advice. Investors should consult with a qualified attorney to discuss their individual circumstances and potential legal actions.
Frequently Asked Questions (FAQ)
What is the class action lawsuit against Vistagen Therapeutics, Inc. about?
The class action lawsuit alleges that Vistagen Therapeutics, Inc. misled investors regarding the viability of its Phase 3 PALISADE-3 trial of fasedienol for treating social anxiety disorder, leading to artificially inflated stock prices.
Who is eligible to participate in the class action?
Investors who purchased or acquired Vistagen Therapeutics, Inc. common stock between April 1, 2024, and December 16, 2025, may be eligible to participate in the class action.
How can I become a lead plaintiff in the class action?
Investors interested in serving as lead plaintiffs should contact Robbins LLP for more information on the process and requirements.
Do I need to participate in the case to receive a recovery?
No, you do not have to participate in the case to be eligible for a recovery. All representation is on a contingency fee basis, meaning shareholders pay no fees or expenses unless a recovery is obtained.
How can I contact Robbins LLP for more information?
Investors can contact Robbins LLP at 1-800-350-6003 or visit their website for more information.
What is Vistagen Therapeutics, Inc.?
Vistagen Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for neuropsychiatric and neurological disorders. Its lead product candidate, fasedienol, is being evaluated for the acute treatment of social anxiety disorder.
What is the current stock price of Vistagen Therapeutics, Inc.?
As of January 16, 2026, Vistagen’s stock (NASDAQ: VTGN) is trading at $0.671 per share, reflecting a decrease of 4.02% from the previous close.
What should investors do if they believe they have been affected by this issue?
Investors who believe they have been affected should contact Robbins LLP to discuss their potential involvement in the class action and to receive guidance on their rights and options.
Is this article providing legal advice?
No, this article is for informational purposes only and does not constitute legal advice. Investors should consult with a qualified attorney to discuss their individual circumstances and potential legal actions.
Where can I find more information about Robbins LLP?
More information about Robbins LLP can be found on their website or by contacting them directly at 1-800-350-6003.
What is the significance of the stock price decline?
The significant decline in Vistagen’s stock price following the disclosure of the trial’s failure indicates the market’s negative reaction to the news and the potential impact on investors who purchased shares at inflated prices.
What are the next steps in the class action process?
The next steps include the appointment of lead plaintiffs, the filing of a consolidated complaint, and the progression of the case through the legal system. Investors interested in participating should stay informed and consult with legal counsel.
How can I stay updated on developments in this case?
Investors can stay updated by contacting Robbins LLP for notifications and by monitoring reputable news sources for updates on the class action and related developments.
What are the potential outcomes of the class action?
Potential outcomes include a settlement or judgment in favor of the class, which could result in financial recovery for eligible investors. The exact outcome will depend on the progression and resolution of the legal proceedings.
What should I do if I have further questions?
If you have further questions, consider consulting with a securities attorney or contacting Robbins LLP directly for more information and guidance.
Is there a deadline to join the class action?
While specific deadlines may apply, investors are encouraged to contact Robbins LLP promptly to discuss their potential involvement and to ensure they meet any applicable deadlines.
What are the risks of participating in a class action?
Participating in a class action carries certain risks, including the possibility of no recovery or a lower recovery than expected. It’s important to consult with legal counsel to understand the potential risks and benefits.
Can I opt out of the class action?
Yes, investors have the option to opt out of the class action if they prefer to pursue individual legal action. Consulting with an attorney can help determine the best course of action based on individual circumstances.
What is the role of the lead plaintiff?
The lead plaintiff represents the interests of the class in directing the litigation. This role involves making key decisions in the case and working with legal counsel to advance the interests of the class members.
How can I verify the legitimacy of this class action notice?
To verify the legitimacy, contact Robbins LLP directly using the contact information provided in the article or visit their official website for more information.
What are the potential benefits of participating in the class action?
Potential benefits include financial recovery for losses incurred due to the alleged misleading statements and the opportunity to hold the company accountable for its actions.
What should I do if I believe I have a claim but missed the deadline?
If you believe you have a claim but missed the deadline, consult with a securities attorney as soon as possible to discuss your options and determine if any exceptions apply.
Can I join the class action if I sold my shares during the class period?
Yes, investors who sold their shares during the class period may still be eligible to participate in the class action. It’s important to consult with legal counsel to understand your rights and options.
What is the significance of the FDA warning letter and import alert for Viatris Inc.?
The FDA warning letter and import alert for Viatris Inc.’s Indore, India facility highlight regulatory challenges that can impact a company’s operations and financial performance, as seen in the case of Viatris Inc.
How can I protect myself from potential investment fraud?
To protect yourself, conduct thorough research before investing, stay informed about the companies you invest in, and consult with financial advisors or legal counsel if you have concerns about potential fraud or misleading information.
What are the implications of the class action for Vistagen Therapeutics, Inc.?
The class action could result in financial liability for Vistagen Therapeutics, Inc. and may lead to changes in corporate governance or business practices to address the alleged issues.
What are the potential outcomes for investors involved in the class action?
Potential outcomes include financial recovery through settlements or judgments, as well as the opportunity to hold the company accountable for its actions.
What are the potential benefits of participating in the class action?
Potential benefits include financial recovery for losses incurred due to the alleged misleading statements and the opportunity to hold the company accountable for its actions.
What should I do if I believe I have a claim but missed the deadline?
If you believe you have a claim but missed the deadline, consult with a securities attorney as soon as possible to discuss your options and determine if any exceptions apply.
| Key Features | Details |
|---|---|
| Class Action Lawsuit | Against Vistagen Therapeutics, Inc. for misleading trial results |
| Trial in Question | Phase 3 PALISADE-3 trial of fasedienol |
| Date Range for Investors | April 1, 2024 – December 16, 2025 |
| Stock Price Drop | From $4.36 to $0.86 following disclosure |
| Current Stock Price | $0.671 as of January 16, 2026 |
Deeper Dive: News & Info About This Topic
HERE Resources
Author: STAFF HERE SAN DIEGO WRITER
The SAN DIEGO STAFF WRITER represents the experienced team at HERESanDiego.com, your go-to source for actionable local news and information in San Diego, San Diego County, and beyond. Specializing in "news you can use," we cover essential topics like product reviews for personal and business needs, local business directories, politics, real estate trends, neighborhood insights, and state news affecting the area—with deep expertise drawn from years of dedicated reporting and strong community input, including local press releases and business updates. We deliver top reporting on high-value events such as Comic-Con International, San Diego County Fair, and San Diego Pride Festival. Our coverage extends to key organizations like the San Diego Regional Chamber of Commerce and United Way of San Diego County, plus leading businesses in biotechnology, healthcare, and technology that power the local economy such as Qualcomm, Illumina, and Scripps Health. As part of the broader HERE network, including HEREAnaheim.com, HEREBeverlyHills.com, HERECostaMesa.com, HERECoronado.com, HEREHollywood.com, HEREHuntingtonBeach.com, HERELongBeach.com, HERELosAngeles.com, HEREMissionViejo.com, and HERESantaAna.com, we provide comprehensive, credible insights into California's dynamic landscape.
